12 April 2021: Clinical Research
Prostate Adenocarcinoma with Brain Metastasis: A Surveillance, Epidemiology, and End Results Database Analysis 2010–2015
Zin W. Myint ABCDEF* , Ayman H. Qasrawi ABCDEFDOI: 10.12659/MSM.930064
Med Sci Monit 2021; 27:e930064
Table 1 Baseline patient characteristics.
| Variables | Brain met at diagnosis (n=187) | No brain met at diagnosis (n=14566) | P value |
|---|---|---|---|
| * | |||
| Median (range) | 67 (42–92) | 71 (34–99) | |
| 75 and younger | 132 (71%) | 9260 (64%) | |
| >75 | 55 (29%) | 5306 (36%) | |
| Caucasian | 141 (75%) | 10845 (75%) | 0.65 |
| African American | 35 (19%) | 2669 (18%) | |
| Other/Unknown | 11 (6%) | 1052 (7%) | |
| ** | 0.46 | ||
| 1 and 2 | 9 (11%) | 8323 (91%) | |
| 3 and 4 | 71 (89%) | 819 (9%) | |
| 0.089 | |||
| Yes | 170 (93%) | 13547 (96%) | |
| No | 12 (7%) | 575 (4%) | |
| Yes | 22 (13%) | 570 (4%) | |
| No | 150 (87%) | 13928 (96%) | |
| Yes | 49 (29%) | 1074 (7%) | |
| No | 119 (71%) | 13292 (93%) | |
| 0.16 | |||
| Yes | 161 (87%) | 13083 (90%) | |
| No | 24 (13%) | 1436 (10%) | |
| Yes | 35 (19%) | 366 (3%) | |
| No | 152 (81%) | 13881 (97%) | |
| 0.20 | |||
| Yes | 25 (13%) | 1528 (10%) | |
| No | 162 (87%) | 13038 (90%) | |
| Alive | 3 (2%) | 463 (3%) | |
| Dead | 132 (71%) | 7044 (48%) | |
| Untraced | 52 (28%) | 7059 (49%) | |
| * Calculated by Mann-Whitney U Test; ** Gleason conversion table 2014. Grade 1 and 2 – groups of patients with Gleason score from 2 to 7 and histology ranging from well differentiated to moderately differentiated. Grade 3 and 4 – groups of patients with Gleason score 8 to 10 and poorly differentiated histology. Met – metastasis; PSA – prostate-specific antigen. | |||